ReviewCancers2022
Recent Advances in Bacteria-Based Cancer Treatment.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer Immunotherapy.Current microbiology · 2025Pooled it
- Engineered probiotic-propelled micro-robot as biological truck for deep tumor penetration and treatment.Materials today. Bio · 2026Article
- What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs.International journal of molecular sciences · 2026Review
- Tumor-targeted aptamer-conjugated engineered bacteria for CXCL9 cytokine delivery in non-small cell lung cancer immunotherapy.Journal of translational medicine · 2026Article
- The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future.Microorganisms · 2026Review
- Biomaterials Based on Bacteria for Cancer Clinical Therapy.Biomaterials research · 2026Review
- Systemic administration ofJournal for immunotherapy of cancer · 2025Article
- Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025Review
- Molecular Mechanisms and Therapeutic Perspectives of Gut Microbiota, Autophagy, and Apoptosis in Cholangiocarcinoma Pathophysiology.International journal of molecular sciences · 2025Review
- Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics.Discover oncology · 2025Review
- Review
- Studying the Oncolytic Activity ofMicroorganisms · 2025Article
- Two homologous sequences of Grp78 and HSP70 represent tumor antigens shared with streptococcal superantigens in eliciting an antitumor immune response: an immunoinformatic investigation.Frontiers in immunology · 2025Article
- The application of bacteria-nanomaterial hybrids in antitumor therapy.Journal of nanobiotechnology · 2024Review
- Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future.Cell communication and signaling : CCS · 2024Review
- Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics againstScience advances · 2024Article
- Microbial Therapy and Breast Cancer Management: Exploring Mechanisms, Clinical Efficacy, and Integration within the One Health Approach.International journal of molecular sciences · 2024Review
- Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy.Pharmaceutics · 2023Review
- Article
- Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Owing to its unique mechanism of abundant pathogen-associated molecular patterns in antitumor immune responses, bacteria-based cancer immunotherapy has recently attracted wide attention. Compared to traditional cancer treatments such as surgery, chemotherapy, radiotherapy, and phototherapy, bacteria-based cancer immunotherapy exhibits the versatile capabilities for suppressing cancer thanks to its preferentially accumulating and proliferating within tumors. In particular, bacteria have demonstrated their anticancer effect through the toxins, and other active components from the cell membrane, cell wall, and dormant spores. More importantly, the design of engineering bacteria with detoxification and specificity is essential for the efficacy of bacteria-based cancer therapeutics. Meanwhile, bacteria can deliver the cytokines, antibody, and other anticancer theranostic nanoparticles to tumor microenvironments by regulating the expression of the bacterial genes or chemical and physical loading. In this review, we illustrate that naïve bacteria and their components can serve as robust theranostic agents for cancer eradication. In addition, we summarize the recent advances in efficient antitumor treatments by genetically engineering bacteria and bacteria-based nanoparticles. Further, possible future perspectives in bacteria-based cancer immunotherapy are also inspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.